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a  b  s  t  r  a  c  t
Pancreatic  cancer  is one  of  the  most  deadly  cancers  with  a nearly  95% mortality  rate.  The
poor response  of  pancreatic  cancer  to  currently  available  therapies  and  the  extremely  low
survival rate  of  pancreatic  cancer  patients  point  to a  critical  need  for alternative  therapeutic
strategies.  The  use  of  reactive  oxygen  species  (ROS)-inducing  agents  has  emerged  as  an
innovative  and  effective  strategy  to treat  various  cancers.  In this  study,  we  investigated
the  potential  of  a known  ROS inducer,  piperlongumine  (PPLGM),  a  bioactive  agent  found
in long  peppers,  to  induce  pancreatic  cancer  cell death in  cell  culture  and  animal  models.
We  found  that  PPLGM  inhibited  the  growth  of  pancreatic  cancer  cell  cultures  by elevating
ROS  levels  and  causing  DNA  damage.  PPLGM-induced  DNA  damage  and  pancreatic  cancer
cell death  was  reversed  by  treating  the  cells  with  an  exogenous  antioxidant.  Similar  to  the
in vitro  studies,  PPLGM  caused  a reduction  in tumor  growth  in  a xenograft  mouse  model  of
human pancreatic  cancer.  Tumors  from  the  PPLGM-treated  animals  showed  decreased  Ki-
67 and  increased  8-OHdG  expression,  suggesting  PPLGM  inhibited  tumor  cell  proliferation
and  enhanced  oxidative  stress.  Taken  together,  our  results  show  that  PPLGM  is an effective
inhibitor for  in  vitro  and in  vivo  growth  of  pancreatic  cancer  cells,  and  that it works  through  a
ROS-mediated  DNA  damage  pathway.  These  ﬁndings  suggest  that  PPLGM  has the  potential
to be used  for  treatment  of pancreatic  cancer.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. Introduction
Pancreatic cancer is one of the most deadly cancers in
he  United States with a 5-year survival rate of less than 6%
1].  The vast majority of pancreatic cancer patients present
ith  advanced disease, at which point surgery is no longer
Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; DCFDA, 2,7-
ichlorodihydroﬂuorescein diacetate; DMSO, dimethyl sulfoxide; GSTP1,
lutathione S-transferase P1; HO1, heme oxygenase 1; NAC, N-acetyl cys-
eine;  PPLGM, piperlongumine; pChk1, phospho checkpoint kinase 1; ROS,
eactive oxygen species; SOD1, superoxide dismutase 1.
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an option [2]. The best chemotherapy currently available
has  a minimal impact on advanced pancreatic cancers, and
extends  patients’ lives by only a couple of months [3]. There
is  a critical need to develop new therapeutic strategies to
enhance  the survival of pancreatic cancer patients.
A new approach for pancreatic cancer treatment is
the  use of reactive oxygen species (ROS)-inducing small
molecules that take advantage of the altered redox state
in  cancer cells [4–6]. Cancer cells exhibit elevated levels of
ROS  as well as antioxidant enzymes [7]. As a result, cancer
cells  are more vulnerable than normal cells to agents that
induce  further oxidative stress or impair the antioxidant
response [8].
Several  ROS-inducing small molecules have been tested
in  clinical trials for the treatment of pancreatic can-
cer. The ROS inducer -lapachone causes cytotoxicity in
cess article under the CC BY-NC-ND license (http://creativecommons.org/
logy Rep310 H. Dhillon et al. / Toxico
NAD(P)H:quinone oxidoreductase (NQO1)-overexpressing
pancreatic tumors by modulating PARP, NAD+/ATP levels,
leading to single-stranded DNA breaks, and necrosis [9,10].
Clinical  trials of -lapachone in combination with gem-
citabine have been used for the treatment of metastatic
pancreatic adenocarcinoma. Further, phase I and II clini-
cal  studies for imexon, a small molecule pro-oxidant have
been  conducted in pancreatic cancer patients [11]. Imexon
induces apoptosis in pancreatic cancer cells by elevating
ROS levels and causing cell cycle arrest [12].
Given the promise of ROS-inducing agents for cancer
treatment, we investigated the effects of the ROS-inducer
piperlongumine (PPLGM) on pancreatic cancer cell death
in  vitro and in vivo. PPLGM is an alkaloid found in the
fruits of long pepper plants that displays potent growth-
inhibitory properties in a variety of cancer cell lines and
various animal models. Interestingly, PPLGM has been
shown to be non-toxic to several normal cell types and tis-
sues  [13,14]. In this study, PPLGM’s effect on ROS levels,
DNA  damage, and cell death were evaluated in cell culture
and  animal models to evaluate the potential of PPLGM as
an  alternative therapeutic approach to treating pancreatic
cancer.
2.  Materials and methods
2.1.  Materials
Piperlongumine (PPLGM) was purchased from Indoﬁne
Chemical Company (Catalog#: P-004, 97%, Hillsborough,
NJ). PPLGM was dissolved in 100% DMSO at a stock concen-
tration of 10 mM and then diluted in water to a working
concentration. The ﬁnal concentration of PPLGM was in
the  range of 0.1–20 M.  pChk1 (S296) and total Chk1
antibodies were purchased from Cell Signaling Technolo-
gies  (Danvers, MA). Mouse anti Ki-67 primary antibody
(clone MM1)  was purchased from Vector Labs (Burlingame,
CA). Anti-8-hydroxy-2′ deoxyguanosine (8-OHdG) mono-
clonal  (N45.1) primary antibody was purchased from Japan
Institute  for the Control of Aging (JaICa, Shizuoka, Japan).
CF633-conguated goat anti-mouse IgG secondary antibody
was  purchased from VWR  (Atlanta, GA).
2.2. Cell culture
The  PANC-1 and MIA  PaCa-2 cell lines were obtained
from ATCC in 2013 (Manassas, VA) and cultured at
37 ◦C with 5% carbon dioxide in Dulbecco’s Modiﬁed
Eagle’s (Thermo Scientiﬁc, Waltham, MA)  medium supple-
mented  with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA). The BxPC-3 cell line was also obtained
from  ATCC and cultured in RPMI-1640 (Thermo Scien-
tiﬁc,  Waltham, MA)  medium supplemented with 10% fetal
bovine  serum. The cell lines were subcultured by enzymatic
digestion with 0.25% trypsin/1 mM EDTA solution (Thermo
Fisher)  when they reached approximately 70% conﬂuency.2.3.  AlamarBlue® cell toxicity assay
PANC-1, MIA  PaCa-2, and BxPC-3 cells (5.0 × 103) were
seeded into individual wells of a 96-well plate, and 24 horts 1 (2014) 309–318
later  were treated with PPLGM (0–20 M)  after which
alamarBlue® (AbD Serotech, Raleigh, NC) was  added at a
ﬁnal  concentration of 10% and incubated at 37 ◦C for 4 h.
The  oxidized form of the dye is converted into the reduced
form  by a mitochondrial enzyme present in the viable
cells. Absorbance was  measured at 570 and 600 nm on a
plate  reader. The cells were monitored daily over a 3-day
period to gauge potential shifts in absorbance. The percent
reduction in alamarBlue® over time for each treatment was
calculated by using the following formula:
% reduction in alamarBlue®
= 117, 216(A1) − 80, 586(A2)
155, 677(B1) − 14, 652(B2)
× 100
In the formula, 117,216 and 80,586 are constants repre-
senting the molar extinction coefﬁcients of alamarBlue®
at 570 and 600 nm,  respectively, in the oxidized form;
whereas 115,677 and 14,652 are constants representing
the molar extinction coefﬁcients of alamarBlue® at 570 and
600  nm,  respectively, in the reduced form. A1 and A2 rep-
resent absorbance of wells treated with PPLGM at 570 and
600  nm,  respectively. B1 and B2 represent absorbance of
untreated wells at 570 and 600 nm,  respectively. A reduc-
tion  in alamarBlue® absorbance correlates to a decrease
in  cell viability. The data represent the % cell viability rel-
ative  to control ± standard deviation in eight replication
wells per treatment for three independent experiments.
The half maximal inhibitory concentrations (IC50) were cal-
culated  by ﬁtting the dose–response curves derived after
plotting the percent cell viability against the log concen-
tration. Eight replicate wells were used per treatment and
the  experiments were performed in triplicate for each cell
line.
2.4.  Clonogenic-survival assay
The clonogenic-survival assay tests the long term sur-
vival  ability of cells in the presence of an anticancer
agent. PANC-1, MIA  PaCa-2, and BxPC-3 cells (5 × 102) were
seeded  into individual wells of a 24-well plate. The next
day,  the cells were treated with 0–20 M PPLGM for 24 h.
The  cells were allowed to grow and form colonies for 14
days.  After 14 days, the colonies were ﬁxed in a solution
of  methanol and acetic acid (3:1), stained with 0.5% crystal
violet,  and counted manually. Four replicate experiments
were performed for each cell line.
2.5. Measurement of ROS by the 2,7-
dichlorodihydroﬂuorescein diacetate (DCF-DA) assay
Approximately 5.0 × 105 cells/ml of all three pancre-
atic cancer cell lines were suspended in culture medium
and treated with 10 M PPLGM for 6 h. After treatment,
cells were harvested by centrifugation and re-suspended
in 10 M DCF-DA (Life Technologies, Carlsbad, CA) in PBS.
The  cells were incubated at 37 ◦C for 30 min  before ﬂow
cytometric analysis using an Accuri C6 Flow Cytometer. The
experiments were performed in triplicate for each cell line.
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.6. Q-PCR
Total RNA was isolated from PANC-1 cells
1.0 × 106 cells) using the Fisher SurePrep Kit (Waltham,
A)  as per the manufacturer’s instructions. 100 ng of total
NA  were reverse transcribed into cDNA using the qScript
DNA  synthesis kit (Quanta Biosciences, Gaithersburg,
D). Primers against human SOD1, GSTP1, and HO1
ere designed using Primer Express software (version
.0, Applied Biosystems), and synthesized by Integrated
NA Technologies (Coralville, IA). Primer sequences
ere as follows, HO-1 forward: AATTCTCTTGGCTG-
CTTCCT; HO-1 reverse: CATAGGCTCCTTCCTCCTTTCC;
STP1 forward: CAGGAGGGCTCACTCAAAGC; GSTP1
everse: AGGTGACGCAGGATGGTATTG; SOD1 forward:
CCTGCATGGATTCCATGTT, SOD1 reverse: TGGCCCAC-
GTGTTTTCT. Steady-state mRNA levels of antioxidant
enes were determined for the cDNAs by real-time PCR
sing  PerfeCTa SYBR Green FastMix (Quanta Biosciences).
he cycling parameters were 95 ◦C for 10 min  followed
y 40 cycles of 95 ◦C for 30 s and 60 ◦C for 1 min  and a
issociation program that included 95 ◦C for 1 min, 55 ◦C
or  30 s and 95 ◦C for 30 s ramping up at 0.2 ◦C/s. One
istinct peak was observed for the primer sets. The fold
hange in mRNA expression was calculated by compar-
ng  the 18S rRNA-normalized threshold cycle numbers
CT) in the PPLGM-treated cancer cells compared to the
MSO-treated cancer cells. Duplicate wells were run for
ach  experiment and the experiments were performed in
riplicate.
.7.  Cell survival assay
For  determining cell survival, human pancreatic can-
er  cell lines (4.0 × 105 cells) were treated with the vehicle
ontrol (0.1% DMSO), 10 M PPLGM, 3 mM N-acetyl cys-
eine  (NAC), and 10 M PPLGM in combination with 3 mM
AC  for 24 h. The next day, images were taken using a Leica
MIL  inverted microscope with a DFC290 digital color cam-
ra.  The effect of treatments on the number of surviving
ancreatic cancer cells can be viewed in the images.
.8. DNA fragmentation assay
MIA PaCa-2 cells (5.0 × 105 cells) were seeded into indi-
idual wells of a 6-well plate, and 24 h later were treated
ith vehicle control (0.1% DMSO), 10 M PPLGM, 3 mM N-
cetyl  cysteine (NAC), and 10 M PPLGM in combination
ith 3 mM NAC for 24 h. After 24 h, the cells were washed
wice with PBS, and the DNA was extracted using DNAzol
eagent (Molecular Research, Cincinnati, OH, USA). Isolated
NA  was resolved on 1.5% agarose gels containing ethid-
um  bromide (EtBr) and images were captured using the
ultiImageTM Light Cabinet (Alpha Innotech, San Leandro,
A). The experiments were performed in triplicate.
.9. Western blotMIA  PaCa-2 cells (1 × 106 cells) were treated with
r without 10 M PPLGM and 5 M GEM for 24 h. Cell
ellets were lysed using an SDS lysis buffer (Cell Signalingorts 1 (2014) 309–318 311
Technologies) containing protease and phosphatase
inhibitors (Roche, Indianapolis, IN). Samples were brieﬂy
sonicated to dissociate cell membranes. Sixty micrograms
of total protein isolated from PPLGM or GEM-treated MIA
PaCa-2  cells were separated on 10% SDS-polyacrylamide
gels at 100 V for 1 h. Proteins were transferred to nitrocel-
lulose membranes at 100 V for 70 min  at 4 ◦C. Blots were
then probed overnight at 4 ◦C with primary antibodies. The
next  day, blots were rinsed with 1× TBS-tween (0.1%) and
probed  with secondary antibody for 1 h at room temper-
ature. The western blots were analyzed using SuperSignal
West Pico Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc, Rockford, IL) and images were captured using
the  MultiImageTM Light Cabinet (Alpha Innotech, San
Leandro, CA). pChk1 (S296) levels were normalized to
total  Chk1 expression. Immunoblots were performed in
triplicate  and the image in the ﬁgure represents one typical
replicate.
2.10.  Nude mouse studies
Six-  to 8-week old female athymic nude mice
(Nu/Nu) were purchased from Charles River Laboratories
(Wilmington, MA). The mice were maintained in ster-
ile  conditions using the Innovive IVC System (Innovive,
San Diego, CA), following the protocol approved by North
Dakota State University’s Institutional Animal Care and Use
Committee  (IACUC). The mice were acclimated for 1 week
before  experimental manipulation. Tumor xenografts were
established by subcutaneous injection of 2.0 × 106 PANC-1
cancer cells in 0.1 ml  PBS in the rear ﬂank of the ani-
mals. Once tumor masses became established, the mice
were  randomly divided into two  groups (n = 8). Group 1
served  as the control group and received dimethyl sul-
foxide  (DMSO, 1%) by intraperitoneal injection. Group 2
received  2.4 mg  PPLGM/kg body weight daily for 30 days
by  intraperitoneal injection. PPLGM was  dissolved initially
in  DMSO and further diluted in PBS before administering
to the mice, and the ﬁnal concentration of DMSO was 1%.
Two  axes of the tumor (L, longitudinal axis; W, shortest
axis) were measured with a caliper three times a week
and  each mouse was  weighed weekly. The tumor vol-
ume  was calculated as: V = (L × W2)/2. Following four weeks
of  experimental treatment, the animals were euthanized
in an isoﬂurane chamber followed by cervical disloca-
tion.
2.11. Immunohistochemistry
Tumor tissues from control and PPLGM-treated mice
were  collected and ﬁxed for 24 h in formaldehyde. Parafﬁn-
embedded 5 m thick sections of tumor tissues were
prepared. Sections were deparafﬁnized with histoclear and
ethanol,  followed by antigen retrieval in 10 mM sodium
citrate buffer (0.05% Tween 20, pH 6.0) using an auto-
clave method. The sections were blocked for 20 min  in
blocking buffer (10% normal goat serum in TBST) and
incubated with primary antibodies (Ki-67 [1:100] and 8-
OHdG  [1:20]) overnight at 4 ◦C. The next day, sections were
incubated with CF633-conjugated goat anti-mouse sec-
ondary  antibody (1:250) for an hour at room temperature,
logy Rep312 H. Dhillon et al. / Toxico
and were visualized using a Zeiss inverted Axio Observer
Z1  microscope after mounting a coverslip using Hard-
set  Mounting media with DAPI (Vector Labs, Burlingame,
CA).
2.12. Statistical analyses
Data  are presented as means ± standard deviation for
at  least 3 independent experiments. The signiﬁcance of
differences between groups was determined using a Stu-
dent’s  t-test with statistical signiﬁcance deﬁned as p < 0.05.
Statistical  analyses were performed using SigmaPlot v12.
3.  Results
3.1. PPLGM causes concentration- and time-dependent
growth inhibition of pancreatic cancer cells
The short-term, growth inhibitory effects of PPLGM on
three  pancreatic cancer cell lines were investigated using
the  alamarBlue® assay. The cell lines were treated with
either the vehicle control (DMSO, <0.1%) or increasing con-
centrations of PPLGM (0.1–20 M)  for 0–3 days, and cell
growth was assessed each day. PPLGM induced a concen-
tration and time-dependent decrease in the viability of
PANC-1,  MIA  PaCa-2, and BxPC-3, with IC50 values of 4.2,
4.6,  and 4.2 M,  respectively, at 72 h (Fig. 1A–C). Twenty
Fig. 1. Effect of PPLGM on the growth of three pancreatic cancer cell lines. The
BxPC-3  were treated with various concentrations (0–20 M) of PPLGM for up to
spectrophotometrically using an alamarBlue® assay at days 0, 1, 2, and 3. The meta
from an oxidized (blue) form to a reduced (purple) form. The data represent the ave
replicate  wells per treatment for three independent experiments. Statistical sign
vs.  vehicle control). (D) The long-term growth of all three cell lines was determin
(0–10  M)  over the course of 14 days by clonogenic survival assay. The data repre
for  PANC-1, MIA PaCa-2, and BxPC-3 cells. Statistical signiﬁcance was  determinedorts 1 (2014) 309–318
micromolar PPLGM signiﬁcantly inhibited the growth of
all  pancreatic cancer cell lines by day 1, while 5 M PPLGM
signiﬁcantly inhibited growth by day 2. BxPC-3 cells were
slightly  more sensitive to lower concentrations of PPLGM
than  PANC-1 and MIA  PaCa-2 cells, where the 2.5 M and
1  M treatments signiﬁcantly reduced BxPC-3 growth at
days  2 and 3, respectively.
3.2.  PPLGM causes a concentration-dependent decrease
in  long-term survival of pancreatic cancer cells
To evaluate the effects of PPLGM on long-term survival
of  pancreatic cancer cell lines, a clonogenic survival assay
was  performed. PANC-1, MIA  PaCa-2, and BxPC-3 cells were
seeded  at a low density in culture dishes, allowed to adhere
overnight, treated with either the vehicle control (DMSO)
or  increasing concentrations of PPLGM (0.1–10 M),  and
then  incubated, undisturbed, for 14 days. The total num-
ber  of colonies formed was  counted for each culture dish.
The  data represent the average number of colonies formed
for  three replicates of the respective treatment groups.
The results show that PPLGM caused a concentration-
dependent decrease in the number of colonies formed for
all  three cell lines as compared to the controls (Fig. 1D).
MIA  PaCa-2 and BxPC-3 cells were particularly sensitive
to  PPLGM, and no cells survived for the 5 and 10 M
treatments.
 three pancreatic cancer cell lines (A) PANC-1, (B) MIA  PaCa-2, and (C)
 3 days. The short-term growth of pancreatic cancer cells was measured
bolic activity of living cells is detected by a change in color of alamarBlue®
rage percent cell viability relative to control ± standard deviation in eight
iﬁcance was  determined by Student’s t-test (p < 0.05 for PPLGM-treated
ed by calculating the fraction of cells surviving in the presence of PPLGM
sent the average ± standard deviation for three independent experiments
 by Student’s t-test (p < 0.05 for PPLGM-treated vs. vehicle control).
logy Reports 1 (2014) 309–318 313
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Table 1
Effect of PPLGM on tumor, organ, and ﬁnal weight of mice.
Control PPLGM
Tumor (mg) 55.9 ± 19.1 27.7 ± 4.7
Kidney (mg) 354.3 ± 13.9 330.8 ± 11.6
Liver (mg) 1105.9 ± 24.1 1088.4 ± 58.0H. Dhillon et al. / Toxico
.3. PPLGM elevates ROS levels in pancreatic cancer cell
ines  without signiﬁcantly altering the expression of
ntioxidant response enzymes
PPLGM is known to cause elevated levels of ROS in can-
er  cell lines [13], and enhanced ROS levels are associated
ith cancer cell death for various agents [15]. Therefore,
e examined the role of ROS in PPLGM-induced pancreatic
ancer cell death. PANC-1, MIA  PaCa-2, and BxPC-3 cells
ere  treated with 10 M PPLGM for 6 h followed by stain-
ng  for 30 min  with the redox-sensitive ﬂuorescent probe
CFDA.  Intracellular ROS oxidize DCFDA to the highly ﬂu-
rescent  DCF compound which can be detected by ﬂow
ytometry. Fig. 2A shows PPLGM increases the production
f  ROS in all three pancreatic cancer cell lines compared
o the vehicle control treatment. The PPLGM-induced ROS
evels  were quantiﬁed and the results show that the MIA
aCa-2  cell line experienced a 24-fold increase in ROS rel-
tive  to the control-treated cells, followed by PANC-1 cells
ith  a 9-fold increase, and Bx-PC3 cells with an 8-fold
ncrease (Fig. 2B).
ROS  levels can increase within a cell by two  pri-
ary mechanisms: (1) increased ROS production or (2)
ecreased antioxidant scavenging. To determine if PPLGM
levates ROS by inhibiting the antioxidant capacity of pan-
reatic  cancer cells, we performed qPCR to measure the
RNA  transcript levels of SOD1, GSTP1, and HO1. The
RNA levels for these antioxidant enzymes were slightly,
ut  not signiﬁcantly (p > 0.05) elevated in PPLGM-treated
ancreatic cancer cells (Fig. 2C).
.4. An exogenous antioxidant partially blocks
PLGM-induced pancreatic cancer cell death
We next evaluated the ability of an exogenous antioxi-
ant to reverse the effects of PPLGM for pancreatic cancer
ell  death. The three pancreatic cancer cell lines were
reated for 24 h with 3 mM N-acetyl cysteine (NAC) alone
nd  in combination with PPLGM. Images of the culture
ishes reveal that PPLGM reduced the number of surviving
ancreatic cancer cells and that NAC could partially block
his  effect (Fig. 2D).
.5.  PPLGM induces DNA damage which is blocked by the
ntioxidant NAC
Increased  ROS levels are known to cause DNA damage.
herefore, a DNA laddering assay was done to investigate
he potential involvement of PPLGM-induced ROS in caus-
ng  DNA damage resulting in pancreatic cancer cell death.
IA  PaCa-2 cells were treated with, DMSO (0.1%), 10 M
PLGM,  or gemcitabine (GEM) as a positive control for 24 h.
NA  was isolated from the cells and loaded onto an agarose
el.  Increased DNA laddering was observed in PPLGM-
reated cells compared to the control cells (Fig. 3A and B)
ndicating that PPLGM causes DNA damage for pancreatic
ancer cells. Further evidence of DNA damage was shown
y  enhanced pChk1 (S296) protein expression in PPLGM-
reated cells as compared to the control cells (Fig. 3C and D).
ells  that were treated with the antioxidant NAC + PPLGMLung (mg) 172.6 ± 8.8 169.5 ± 5.3
Spleen (mg) 102.4 ± 12.8 103.7 ± 7.2
Final weight (g) 21.8 ± 1.1 21.7 ± 0.6
showed reduced DNA damage compared to those treated
with  PPLGM alone (Fig. 3E and F).
3.6. PPLGM suppresses the growth of tumor in a mouse
xenograft model
Given  the promising response of pancreatic cancer
cell lines to PPLGM, we chose to further investigate the
anti-cancer effects of PPLGM in an animal model of pan-
creatic cancer. PANC-1 human pancreatic cancer cells were
injected  subcutaneously into athymic nude mice. Tumor
growth was  signiﬁcantly suppressed in mice treated with
2.4  mg  PPLGM/kg (daily for 30 days) as compared to those
treated with DMSO (1%) vehicle (Fig. 4). PPLGM-treated
animals had, on average, tumors that were 50% the mass of
tumors  from control-treated animals (Table 1). The PPLGM
treatment was  well-tolerated and no signiﬁcant changes
were detected in overall animal mass or organ mass, as
shown  in Table 1.
3.7.  PPLGM decreases proliferation and increases DNA
damage in pancreatic tumors
Ki-67 cell proliferation and 8-hydroxy-2′-
deoxyguanosine (8-OHdG) oxidative DNA damage
markers were examined by immunohistochemical
staining for PPLGM-treated and vehicle-treated tumors
harvested from the mice. The tumors obtained from the
PPLGM-treated mice exhibited notably less Ki-67-positive
cells compared with tumors from the control mice (Fig. 5).
Furthermore, tumors from PPLGM-treated mice showed
markedly higher 8-OHdG levels compared with tumors
from  control mice (Fig. 5).
4. Discussion
ROS-inducing agents are an attractive alternative
approach for treating pancreatic cancer [5,16,17]. The ROS-
inducing  agents -lapachone and imexon induce apoptosis
and  necrosis in pancreatic cancer cells, and have been
investigated in clinical trials for the treatment of pancreatic
cancers [9–11]. Therefore, we investigated the potential
of  the small-molecule ROS inducer, PPLGM, for pancreatic
cancer cell death. PPLGM is known to cause cancer-
selective cell death through a ROS-dependent mechanism
[13]. Here we show that PPLGM is toxic to PANC-1, MIA
PaCa-2, and BxPC-3 pancreatic cancer cells. The cytotoxic
effects of PPLGM have previously been shown in PANC-
1  and MIA  PaCa-2 cells [13]. Both of these cells lines are
K-ras  mutant whereas BxPC-3 cells contain wild-type K-
ras.  Our data supports previous results and extends the
314 H. Dhillon et al. / Toxicology Reports 1 (2014) 309–318
Fig. 2. ROS-dependent effects of PPLGM on pancreatic cancer cells. (A) PANC-1, MIA  PaCa-2, and BxPC-3 cells were treated with or without 10 M PPLGM
for  6 h and analyzed for DCF (an indicator of ROS levels) ﬂuorescence. The red trace shows the ﬂuorescence intensity for DCF in the control-treated cells
while  the blue trace shows values for the PPLGM-treated cells. (B) The DCF ﬂuorescence intensity obtained in part A was quantiﬁed for each PPLGM-treated
cell  line and related to its respective control and represented as mean ﬂuorescence. (C) PANC-1 cells were treated with 0 or 10 M PPLGM for 24 h and
mRNA  expression of the antioxidant genes SOD, GSTP-1, and HO-1 was  assessed by Q-PCR. 18S rRNA expression in the control and PPLGM-treated cells
was  used to normalize the data. The mRNA expression fold change for SOD, GSTP-1, and HO-1 are shown for PPLGM-treated cells compared to the control
cells.  (D) PANC-1, MIA  PaCa-2, and BxPC-3 cells were treated with the vehicle (Control), the antioxidant NAC (3 mM), 10 M PPLGM, or 3 mM NAC and
10  M PPLGM for 24 h. The images representing cell survival were taken the next day. The data represent a typical experiment or the average ± standard
deviation  for three independent experiments.
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Fig. 3. Effect of PPLGM and NAC on DNA damage. (A) MIA  PaCa-2 cells were treated for 24 h with 10 M PPLGM or 5 M gemcitabine (GEM) as positive
control.  The DNA damage was assessed by DNA fragmentation assay on a 1.5% agarose gel and images were captured. (B) Images were quantiﬁed using
ImageJ  software. The intensity of DNA damage in the control lane was  compared to the PPLGM and GEM-treated lanes. Densitometry shows the results of
PPLGM  and GEM treatment on DNA fragmentation normalized to the amount of DNA fragmentation in the control in three replicate experiments ± standard
deviation.  (C) MIA  PaCa-2 cells were treated for 24 h with 10 M PPLGM or 5 M GEM as positive control. The cells were lysed to collect protein for western
blotting.  60 g protein was  loaded into each lane and probed with pChk1 (S296) and total Chk1 antibodies. (D) Quantiﬁcation of pChk1 (S296) relative
to  total Chk1 protein was  performed by ImageJ software. Densitometry shows the results of PPLGM and GEM treatment on pChk1 (S296) expression
normalized to total Chk1 in three replicates ± standard deviation. (E) MIA  PaCa-2 cells were treated with the vehicle, 10 M PPLGM alone, 3 mM NAC alone,
or  PPLGM in combination with NAC for 24 h and DNA damage was assessed by DNA fragmentation assay. (F) Densitometry shows the results of PPLGM and
NAC  treatment on DNA fragmentation normalized to the amount of DNA fragmentation in the control in three replicate experiments ± standard deviation
where  * denotes statistical signiﬁcance (p < 0.05).
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Fig. 4. In vivo effects of PPLGM in a PANC-1 xenograft mouse model. Intraperitoneal injections of DMSO (1%) and PPLGM (2.4 mg/kg) were administered
daily  in untreated () and PPLGM-treated mice (), respectively, for 30 days. Subcutaneous PANC-1 tumors were measured every three days. The data
represent  mean % tumor volume relative to control ± standard deviation for 8 animals per group, where * denotes statistically signiﬁcant differences
(p  < 0.05).
onse in
nd 8-OH
 both KiFig. 5. Effects of PPLGM on cell proliferation and the oxidative stress resp
PPLGM-treated  animals and were sectioned and stained for Ki-67 (pink) a
show  one representative slide for control and PPLGM-treated animals for
research to pancreatic cancer cell lines harboring wild type
K-ras.  Further, PPLGM interferes with redox homeosta-
sis by elevating ROS levels in all three cell lines without
affecting antioxidant enzymes. Additionally, PPLGM causes
DNA  damage in the MIA  PaCa-2 cells. PPLGM-induced
DNA damage was reduced in cells treated with an antiox-
idant NAC, suggesting PPLGM-induced ROS is responsible
for  DNA damage in these cells. PPLGM also showed anti-
cancer  effects in vivo. For PANC-1 xenografts in nude mice,
PPLGM  signiﬁcantly reduced tumor volume compared to
the  vehicle control. PPLGM-treated tumors displayed ele-
vated  levels of an oxidative DNA damage marker (8-OHdG)
and  reduced expression of a proliferation marker (Ki-67). PANC-1 xenograft tumors. The tumors were harvested from control and
dG (red) expression. DAPI (blue) was  used to stain the nuclei. The images
-67 and 8-OHdG.
We  suggest that ROS-mediated DNA damage plays a role in
PPLGM-induced cell death in vitro and in vivo for pancreatic
cancer.
Mutations in the K-ras oncogene are detected in the vast
majority (>90%) of pancreatic cancers and are thought to
play  an important role in tumor development, progression,
and resistance to chemotherapy and radiotherapy [18].
Cancer  patients harboring K-ras mutations often have poor
prognoses  and limited treatment options [19,20]. In this
study,  we compared the effects of PPLGM on the growth of
three  different pancreatic cancer cell lines, PANC-1, MIA
PaCa-2  and BxPC-3. PANC-1 and MIA  PaCa-2 cell lines
harbor K-ras mutation whereas BxPC-3 cell line contains
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ild-type K-ras. We found that PPLGM was sensitive to all
hree  cell lines irrespective of the K-ras mutation (Fig. 1).
his  is a promising result since it suggests that PPLGM can
e  an effective treatment option even for pancreatic cancer
atients  with oncogenic K-ras mutation that are resistant
o  the currently available therapies.
ROS are constantly generated and eliminated in biolog-
cal  systems, and play an important role in cell signaling
athways [21]. PPLGM has previously been shown to cause
nhanced production of hydrogen peroxide and nitric oxide
evels  in cancer cells but not healthy cells. The anti-
ancer effects of PPLGM in cancer cells were attributed
o modulation of glutathione S-transferase (GSTP1) activ-
ty  and glutathione (GSH) levels [13]. However, our study
hows  that PPLGM elevated ROS levels in all three pancre-
tic  cancer cells without signiﬁcantly affecting the mRNA
xpression of three key antioxidant enzymes. Excessive
roduction of ROS can result in many types of DNA damage
ncluding single- or double-strand breaks, base modiﬁca-
ions, deoxyribose modiﬁcation, and DNA cross linking.
ild  DNA damage can be repaired with or without cell cycle
rrest.  However, severe DNA damage leads to mutations
r  induction of cell death or senescence [22]. We  found
hat  PPLGM increases DNA laddering and pChk1 (S296)
xpression in pancreatic cancer cells, and the antioxi-
ant NAC could not only block PPLGM-induced pancreatic
ancer death but also offer signiﬁcant protection against
NA  damage. Therefore, ROS-mediated DNA damage is
he  mechanism for pancreatic cancer cell death but the
ype  of cell death via DNA damage needs further investi-
ation.
This  study is the ﬁrst to investigate the anti-tumor efﬁ-
acy  of PPLGM for an animal model of pancreatic cancer.
e  found that PPLGM (2.4 mg/kg/day for 30 days) signiﬁ-
antly inhibited pancreatic tumor growth in the nude mice
elative  to the vehicle control treatment. The ﬁnal tumor
asses from PPLGM-treated animals were 50% lower than
umors  obtained from control-treated animals. Our results
re  in agreement with previous studies that show intraperi-
oneal  administration of 1.5 mg/kg PPLGM suppresses the
rowth  of bladder, breast, lung and melanoma xenografts
y  50–80% nude in mice [13]. However, several mecha-
isms including oxidative stress can be involved in tumor
rowth  inhibition. Interestingly, the most abundant oxida-
ive  DNA lesion produced in response to oxidative stress is
-hydroxydeoxy guanosine (8-OHdG). Many studies have
eported  an elevation of 8-OHdG levels in various human
ancers and animal models of tumors [23,24]. Our results
how  that PPLGM markedly increased the levels of 8-OHdG
n  tumors which may  contribute to decreased cell prolifer-
tion  and tumor growth inhibition.
Taken together, our results demonstrate that PPLGM-
nduced cell death in human pancreatic cancer cells is
ediated by ROS-induced DNA damage. Moreover, PPLGM
igniﬁcantly suppressed the growth of pancreatic tumor
enografts by causing oxidative DNA damage and reduced
ell  proliferation. Our studies provide a rationale for
he  development of PPLGM as chemotherapeutic agent
gainst pancreatic cancer in the clinical setting. Further
tudies evaluating the anti-tumor effects of PPLGM for nor-
al  and K-ras mutant pancreatic tumors in combinationorts 1 (2014) 309–318 317
with chemotherapy are needed to advance this treatment
approach to a clinical setting.
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